Byung Gun Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Byung Gun Lim has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Il Ok Lee
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
21 shared publications Heezoo Kim
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
19 shared publications- Young Ju Won
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
15 shared publications - Young Sung Kim
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
15 shared publications - Seok Kyeong Oh
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
13 shared publications Myoung Hoon Kong
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
12 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (4) , 427-443
Effects of remimazolam on postoperative delirium in adults undergoing general anesthesia: a systematic review and meta-analysis
Benzodiazepines have traditionally been associated with postoperative delirium (POD), but the effect of remimazolam on POD remains uncertain. This systematic review and meta-analysis evaluated the incidence of POD and perioperative safety outcomes associated with remimazolam in adults undergoing general anesthesia. We searched databases from inception through April 27, 2025, and included randomized controlled trials and non-randomized studies comparing remimazolam with conventional anesthetic agents in adults undergoing general anesthesia. The primary outcome was POD incidence, and secondary outcomes comprised perioperative safety measures. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seventeen studies involving 3,180 patients were included. POD incidence did not differ significantly between the remimazolam and control groups (risk ratio [RR], 0.88; 95% confidence interval [CI], 0.71–1.09; I2 = 0%). Similarly, the incidence of intraoperative hypotension did not differ significantly between groups (RR, 0.77; 95% CI, 0.56–1.06). Remimazolam was associated with lower incidences of vasopressor administration (RR, 0.62; 95% CI, 0.41–0.93) and bradycardia (RR, 0.78; 95% CI, 0.62–0.99). Time to eye opening and the incidence of postoperative nausea and vomiting did not differ significantly between groups. The certainty of evidence was very low for POD and low or moderate for secondary outcomes. POD incidence did not differ significantly between remimazolam and conventional anesthetic agents in adults undergoing general anesthesia. Some secondary outcomes suggested a potentially favorable hemodynamic profile; however, the evidence was limited and heterogeneous. Further trials using standardized POD assessment tools and prespecified hemodynamic endpoints are warranted.
- 31 October 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (4) , 427-443
Open AccessEffects of remimazolam on postoperative delirium in adults undergoing general anesthesia: a systematic review and meta-analysis
Benzodiazepines have traditionally been associated with postoperative delirium (POD), but the effect of remimazolam on POD remains uncertain. This systematic review and meta-analysis evaluated the incidence of POD and perioperative safety outcomes associated with remimazolam in adults undergoing general anesthesia. We searched databases from inception through April 27, 2025, and included randomized controlled trials and non-randomized studies comparing remimazolam with conventional anesthetic agents in adults undergoing general anesthesia. The primary outcome was POD incidence, and secondary outcomes comprised perioperative safety measures. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seventeen studies involving 3,180 patients were included. POD incidence did not differ significantly between the remimazolam and control groups (risk ratio [RR], 0.88; 95% confidence interval [CI], 0.71–1.09; I2 = 0%). Similarly, the incidence of intraoperative hypotension did not differ significantly between groups (RR, 0.77; 95% CI, 0.56–1.06). Remimazolam was associated with lower incidences of vasopressor administration (RR, 0.62; 95% CI, 0.41–0.93) and bradycardia (RR, 0.78; 95% CI, 0.62–0.99). Time to eye opening and the incidence of postoperative nausea and vomiting did not differ significantly between groups. The certainty of evidence was very low for POD and low or moderate for secondary outcomes. POD incidence did not differ significantly between remimazolam and conventional anesthetic agents in adults undergoing general anesthesia. Some secondary outcomes suggested a potentially favorable hemodynamic profile; however, the evidence was limited and heterogeneous. Further trials using standardized POD assessment tools and prespecified hemodynamic endpoints are warranted.
- Open Access
- 31 October 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (4) , 553-566
Safety and recovery of rocuronium and sugammadex versus cisatracurium or atracurium and pyridostigmine in surgical patients with chronic kidney disease: a multicenter retrospective propensity score-matched study
Background: Rocuronium and sugammadex are used cautiously in patients with chronic kidney disease (CKD) undergoing anesthesia because of delayed excretion. This multicenter retrospective study explored the safety and recovery of rocuronium–sugammadex compared to cisatracurium/atracurium–pyridostigmine in patients with CKD.Methods: Patients with CKD who received rocuronium–sugammadex (RS group) or cisatracurium/atracurium–pyridostigmine (CP group) between 2020 and 2021 at three tertiary referral hospitals were included. Propensity score-matching was performed using a logistic regression model. The primary outcomes were safety-related indicators (e.g., reintubation, deferred extubation, and desaturation). Secondary outcomes included recovery-related profiles (e.g., extubation time). Subgroup analyses were conducted according to the CKD stage.Results: Of the total 1,241 patients (RS = 630, CP = 611), 804 (402 per group) were matched and analyzed. Among them, 51.1% had advanced CKD (estimated glomerular filtration rate < 30 ml/min/1.73 m2). Primary safety outcomes, including the incidence of reintubation within 48 h (RS: 1.24% vs. CP: 1.24%, P = 1.000) and deferred extubation (1.74% vs. 1.49%, P = 0.780), were not significantly different. Postoperative desaturation and renal outcomes were similar between groups. Extubation time was shorter in the RS group than in the CP group (median 7.00vs. 8.00 min, P = 0.005).Conclusions: Rocuronium–sugammadex demonstrated no clear signal of increased major respiratory or renal risk compared with cisatracurium/atracurium–pyridostigmine in patients with CKD. Although the extubation time was shorter in the RS group, this exploratory finding must be interpreted cautiously because of the heterogeneous practice and limited quantitative neuromuscular monitoring (22%).
- 31 October 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (4) , 553-566
Open AccessSafety and recovery of rocuronium and sugammadex versus cisatracurium or atracurium and pyridostigmine in surgical patients with chronic kidney disease: a multicenter retrospective propensity score-matched study
Background: Rocuronium and sugammadex are used cautiously in patients with chronic kidney disease (CKD) undergoing anesthesia because of delayed excretion. This multicenter retrospective study explored the safety and recovery of rocuronium–sugammadex compared to cisatracurium/atracurium–pyridostigmine in patients with CKD.Methods: Patients with CKD who received rocuronium–sugammadex (RS group) or cisatracurium/atracurium–pyridostigmine (CP group) between 2020 and 2021 at three tertiary referral hospitals were included. Propensity score-matching was performed using a logistic regression model. The primary outcomes were safety-related indicators (e.g., reintubation, deferred extubation, and desaturation). Secondary outcomes included recovery-related profiles (e.g., extubation time). Subgroup analyses were conducted according to the CKD stage.Results: Of the total 1,241 patients (RS = 630, CP = 611), 804 (402 per group) were matched and analyzed. Among them, 51.1% had advanced CKD (estimated glomerular filtration rate < 30 ml/min/1.73 m2). Primary safety outcomes, including the incidence of reintubation within 48 h (RS: 1.24% vs. CP: 1.24%, P = 1.000) and deferred extubation (1.74% vs. 1.49%, P = 0.780), were not significantly different. Postoperative desaturation and renal outcomes were similar between groups. Extubation time was shorter in the RS group than in the CP group (median 7.00vs. 8.00 min, P = 0.005).Conclusions: Rocuronium–sugammadex demonstrated no clear signal of increased major respiratory or renal risk compared with cisatracurium/atracurium–pyridostigmine in patients with CKD. Although the extubation time was shorter in the RS group, this exploratory finding must be interpreted cautiously because of the heterogeneous practice and limited quantitative neuromuscular monitoring (22%).
- Open Access
- 2 September 2026
- Published by Springer Nature in BMC Health Services Research
Pediatric anesthesiologist shortage in South Korea: a nationwide survey of workforce and training
- 2 September 2026
- Published by Springer Nature in BMC Health Services Research
Open AccessPediatric anesthesiologist shortage in South Korea: a nationwide survey of workforce and training
- Open Access
- 31 July 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (3) , 296-311
Korean guidelines for pediatric procedural sedation
Safe and effective pediatric sedation depends on multiple factors, including the precise selection of sedative agents, provider expertise, availability of age-appropriate monitoring equipment, and the patients’ individual circumstances. These revised clinical practice guidelines, developed by the Korean Society of Pediatric Anesthesiologists, aim to promote safe and effective pediatric sedation across diverse clinical settings in Korea, thereby enhancing patient safety and standardizing care. These guidelines represent a comprehensive update to the first edition published in 2017, systematically revised through an expert consensus model to reflect the rapidly evolving clinical landscape. The revision prioritized clinical utility and consistency, incorporating the latest pharmacological and technological advancements, while optimizing the content for practical bedside use. Key recommendations cover the entire sedation continuum, including the identification of qualified providers, pre-sedation patient evaluation and fasting requirements, age-specific risk assessment, monitoring of the respiratory and cardiovascular systems, level of sedation, management of respiratory complications, and structured discharge criteria. These recommendations are intended to guide healthcare providers and guardians in sedation-related decision-making for various diagnostic and therapeutic procedures. Depending on the clinical needs and institutional limitations of the primary, secondary, and tertiary care facilities, sedation providers may apply these recommendations directly, adapt them to their specific environments, or use them as a foundational framework for internal protocols.
- 31 July 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (3) , 296-311
Open AccessKorean guidelines for pediatric procedural sedation
Safe and effective pediatric sedation depends on multiple factors, including the precise selection of sedative agents, provider expertise, availability of age-appropriate monitoring equipment, and the patients’ individual circumstances. These revised clinical practice guidelines, developed by the Korean Society of Pediatric Anesthesiologists, aim to promote safe and effective pediatric sedation across diverse clinical settings in Korea, thereby enhancing patient safety and standardizing care. These guidelines represent a comprehensive update to the first edition published in 2017, systematically revised through an expert consensus model to reflect the rapidly evolving clinical landscape. The revision prioritized clinical utility and consistency, incorporating the latest pharmacological and technological advancements, while optimizing the content for practical bedside use. Key recommendations cover the entire sedation continuum, including the identification of qualified providers, pre-sedation patient evaluation and fasting requirements, age-specific risk assessment, monitoring of the respiratory and cardiovascular systems, level of sedation, management of respiratory complications, and structured discharge criteria. These recommendations are intended to guide healthcare providers and guardians in sedation-related decision-making for various diagnostic and therapeutic procedures. Depending on the clinical needs and institutional limitations of the primary, secondary, and tertiary care facilities, sedation providers may apply these recommendations directly, adapt them to their specific environments, or use them as a foundational framework for internal protocols.
- Open Access
- 21 July 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (3) , 375-390
Efficacy and safety of sugammadex for reversal of neuromuscular blockade in pediatric patients: an updated systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Background: Sugammadex has recently been approved globally for use in pediatric patients aged ≥ 2 years. This meta-analysis with trial sequential analysis (TSA) evaluated the efficacy and safety of sugammadex for reversal of neuromuscular blockade (NMB) in pediatric patients.Methods: PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched from inception to December 31, 2023. Randomized controlled trials (RCTs) evaluating sugammadex in pediatric patients were included. Efficacy outcomes were time to recovery to a train-of-four (TOF) ratio ≥ 0.9 and extubation time. Safety outcomes included overall post-anesthetic adverse events, bradycardia, tachycardia, postoperative nausea and vomiting (PONV), recurarization, and desaturation. Data were analyzed using RevMan, and TSA was performed using Copenhagen Trial Unit software.Results: A total of 21 RCTs (n=1,394 pediatric patients) were included in the study. Time to TOF ratio ≥ 0.9 was significantly shorter with sugammadex than with control (neostigmine or placebo) for both 2 mg/kg (mean difference [95% confidence interval], –6.03 [–7.85 to –4.21] min) and 4 mg/kg (–30.06 [–37.58 to –22.55] min). The extubation time was shorter with sugammadex (–14.26 [–17.22 to –11.30] min). The TSA for both efficacy outcomes indicated that the required information size had been reached, suggesting that additional trials are unlikely to change the efficacy conclusions. PONV, tachycardia, and desaturation occurred less frequently with sugammadex, whereas the overall post-anesthetic adverse events, recurarization, and bradycardia were comparable.Conclusions: Sugammadex was associated with faster and more effective reversal of rocuronium-induced NMB in pediatric patients.
- 21 July 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (3) , 375-390
Open AccessEfficacy and safety of sugammadex for reversal of neuromuscular blockade in pediatric patients: an updated systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Background: Sugammadex has recently been approved globally for use in pediatric patients aged ≥ 2 years. This meta-analysis with trial sequential analysis (TSA) evaluated the efficacy and safety of sugammadex for reversal of neuromuscular blockade (NMB) in pediatric patients.Methods: PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched from inception to December 31, 2023. Randomized controlled trials (RCTs) evaluating sugammadex in pediatric patients were included. Efficacy outcomes were time to recovery to a train-of-four (TOF) ratio ≥ 0.9 and extubation time. Safety outcomes included overall post-anesthetic adverse events, bradycardia, tachycardia, postoperative nausea and vomiting (PONV), recurarization, and desaturation. Data were analyzed using RevMan, and TSA was performed using Copenhagen Trial Unit software.Results: A total of 21 RCTs (n=1,394 pediatric patients) were included in the study. Time to TOF ratio ≥ 0.9 was significantly shorter with sugammadex than with control (neostigmine or placebo) for both 2 mg/kg (mean difference [95% confidence interval], –6.03 [–7.85 to –4.21] min) and 4 mg/kg (–30.06 [–37.58 to –22.55] min). The extubation time was shorter with sugammadex (–14.26 [–17.22 to –11.30] min). The TSA for both efficacy outcomes indicated that the required information size had been reached, suggesting that additional trials are unlikely to change the efficacy conclusions. PONV, tachycardia, and desaturation occurred less frequently with sugammadex, whereas the overall post-anesthetic adverse events, recurarization, and bradycardia were comparable.Conclusions: Sugammadex was associated with faster and more effective reversal of rocuronium-induced NMB in pediatric patients.
- Open Access
- 30 April 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (2) , 258-266
Changes in postoperative pneumonia incidence after the pandemic: a retrospective observational study using a common data model
Background: The coronavirus disease 2019 (COVID-19) pandemic has profoundly influenced surgical practice and perioperative care, but its impact on postoperative pneumonia incidence remains unclear.Methods: We conducted a retrospective cohort study using the Observational Medical Outcomes Partnership–Common Data Model databases from 17 Korean hospitals. Based on the inpatient surgery date, patients were classified into prepandemic (January 2018–December 2019) and postpandemic groups (January 2020–December 2021). Postoperative pneumonia was identified within 30 days after surgery. Logistic regression analysis assessed the independent effects of the pandemic, age, anesthetic technique, and their interaction.Results: The overall incidence of postoperative pneumonia per 10,000 persons changed slightly from 12.38 prepandemic to 12.99 postpandemic (+4.94%). Younger patients (< 70 years) demonstrated decreased incidence (8.47→7.97, −5.81%), whereas older patients (≥ 70 years) demonstrated increased incidence (28.97→31.97, +10.36%). Considerable interhospital variation was observed, with some hospitals reporting increases exceeding 100%, while others reporting declines exceeding 80%. Overall postoperative pneumonia risk was similar between the pre- and postpandemic periods (odds ratio [OR], 0.893; 95% confidence interval [CI], 0.787–1.015). Older age (≥ 70 years) was strongly associated with higher risk (OR, 2.816; 95% CI, 2.383–3.328), and a significant postpandemic×age interaction indicated that older patients were disproportionately affected (OR, 1.385; 95% CI, 1.145–1.675).Conclusions: The COVID-19 pandemic did not substantially change the overall incidence of postoperative pneumonia, although variations existed across hospitals and age groups. Older age remained the strongest risk factor. Further studies are warranted to clarify the underlying causes and optimize perioperative infection control.
- 30 April 2026
- Published by The Korean Society of Anesthesiologists in Anesthesia and Pain Medicine
- Vol. 21 (2) , 258-266
Open AccessChanges in postoperative pneumonia incidence after the pandemic: a retrospective observational study using a common data model
Background: The coronavirus disease 2019 (COVID-19) pandemic has profoundly influenced surgical practice and perioperative care, but its impact on postoperative pneumonia incidence remains unclear.Methods: We conducted a retrospective cohort study using the Observational Medical Outcomes Partnership–Common Data Model databases from 17 Korean hospitals. Based on the inpatient surgery date, patients were classified into prepandemic (January 2018–December 2019) and postpandemic groups (January 2020–December 2021). Postoperative pneumonia was identified within 30 days after surgery. Logistic regression analysis assessed the independent effects of the pandemic, age, anesthetic technique, and their interaction.Results: The overall incidence of postoperative pneumonia per 10,000 persons changed slightly from 12.38 prepandemic to 12.99 postpandemic (+4.94%). Younger patients (< 70 years) demonstrated decreased incidence (8.47→7.97, −5.81%), whereas older patients (≥ 70 years) demonstrated increased incidence (28.97→31.97, +10.36%). Considerable interhospital variation was observed, with some hospitals reporting increases exceeding 100%, while others reporting declines exceeding 80%. Overall postoperative pneumonia risk was similar between the pre- and postpandemic periods (odds ratio [OR], 0.893; 95% confidence interval [CI], 0.787–1.015). Older age (≥ 70 years) was strongly associated with higher risk (OR, 2.816; 95% CI, 2.383–3.328), and a significant postpandemic×age interaction indicated that older patients were disproportionately affected (OR, 1.385; 95% CI, 1.145–1.675).Conclusions: The COVID-19 pandemic did not substantially change the overall incidence of postoperative pneumonia, although variations existed across hospitals and age groups. Older age remained the strongest risk factor. Further studies are warranted to clarify the underlying causes and optimize perioperative infection control.
- Open Access
- 4 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5491
Influence of Remimazolam and Propofol on Intraoperative Motor Evoked Potentials During Spinal Surgery: A Randomized Crossover Trial
Background/Objectives: Total intravenous anesthesia (TIVA) typically combines propofol and remifentanil. Remifentanil exerts minimal influence on motor evoked potential (MEP), whereas propofol partially reduces MEP amplitude. Remimazolam, a novel agent, is a component of TIVA. However, evidence of remimazolam on MEP is limited. We aimed to compare the effects of propofol and remimazolam, combined with remifentanil, on relative MEP depression. Methods: Using a crossover design, 18 patients undergoing spine surgery were randomly assigned to receive either propofol or remimazolam as the first agent. In the propofol first sequence, anesthesia was induced and maintained with propofol, which was then switched to remimazolam 60 min after surgery. In the remimazolam first sequence, remimazolam was used first and then switched to propofol. The primary outcomes measured were the MEP amplitude and latency. Results: MEP amplitude and latency during propofol and remimazolam infusions were as follows: amplitude (mean (SD); 635.3 (399.1) vs. 738.4 (480.4) μV, p = 0.047) and latency (median [IQR]; 22.4 [20.3–24.6] vs. 21.4 [19.6–23.5] ms, p = 0.070), indicating propofol caused greater depression in amplitude than remimazolam. However, an incident of severe body movement disrupting surgery occurred under remimazolam anesthesia in a young, healthy male patient, although bispectral index remained below 60. This suggests that remimazolam, at hypnotic levels similar to propofol, may result in reduced akinesia in major surgeries, such as spinal surgery, when neuromuscular blockade is not employed. Conclusions: Remimazolam demonstrated comparable or superior effects to propofol on MEP latency and amplitude when combined with remifentanil during spinal surgery, rendering it a potential alternative to propofol for MEP monitoring.
- 4 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5491
Open AccessInfluence of Remimazolam and Propofol on Intraoperative Motor Evoked Potentials During Spinal Surgery: A Randomized Crossover Trial
Background/Objectives: Total intravenous anesthesia (TIVA) typically combines propofol and remifentanil. Remifentanil exerts minimal influence on motor evoked potential (MEP), whereas propofol partially reduces MEP amplitude. Remimazolam, a novel agent, is a component of TIVA. However, evidence of remimazolam on MEP is limited. We aimed to compare the effects of propofol and remimazolam, combined with remifentanil, on relative MEP depression. Methods: Using a crossover design, 18 patients undergoing spine surgery were randomly assigned to receive either propofol or remimazolam as the first agent. In the propofol first sequence, anesthesia was induced and maintained with propofol, which was then switched to remimazolam 60 min after surgery. In the remimazolam first sequence, remimazolam was used first and then switched to propofol. The primary outcomes measured were the MEP amplitude and latency. Results: MEP amplitude and latency during propofol and remimazolam infusions were as follows: amplitude (mean (SD); 635.3 (399.1) vs. 738.4 (480.4) μV, p = 0.047) and latency (median [IQR]; 22.4 [20.3–24.6] vs. 21.4 [19.6–23.5] ms, p = 0.070), indicating propofol caused greater depression in amplitude than remimazolam. However, an incident of severe body movement disrupting surgery occurred under remimazolam anesthesia in a young, healthy male patient, although bispectral index remained below 60. This suggests that remimazolam, at hypnotic levels similar to propofol, may result in reduced akinesia in major surgeries, such as spinal surgery, when neuromuscular blockade is not employed. Conclusions: Remimazolam demonstrated comparable or superior effects to propofol on MEP latency and amplitude when combined with remifentanil during spinal surgery, rendering it a potential alternative to propofol for MEP monitoring.
- Open Access
- 16 September 2024
- Published by JMIR Publications Inc. in JMIR Medical Education
- Vol. 10, e56859
Performance of ChatGPT in the In-Training Examination for Anesthesiology and Pain Medicine Residents in South Korea: Observational Study
Background: ChatGPT has been tested in health care, including the US Medical Licensing Examination and specialty exams, showing near-passing results. Its performance in the field of anesthesiology has been assessed using English board examination questions; however, its effectiveness in Korea remains unexplored. Objective: This study investigated the problem-solving performance of ChatGPT in the fields of anesthesiology and pain medicine in the Korean language context, highlighted advancements in artificial intelligence (AI), and explored its potential applications in medical education. Methods: We investigated the performance (number of correct answers/number of questions) of GPT-4, GPT-3.5, and CLOVA X in the fields of anesthesiology and pain medicine, using in-training examinations that have been administered to Korean anesthesiology residents over the past 5 years, with an annual composition of 100 questions. Questions containing images, diagrams, or photographs were excluded from the analysis. Furthermore, to assess the performance differences of the GPT across different languages, we conducted a comparative analysis of the GPT-4’s problem-solving proficiency using both the original Korean texts and their English translations. Results: A total of 398 questions were analyzed. GPT-4 (67.8%) demonstrated a significantly better overall performance than GPT-3.5 (37.2%) and CLOVA-X (36.7%). However, GPT-3.5 and CLOVA X did not show significant differences in their overall performance. Additionally, the GPT-4 showed superior performance on questions translated into English, indicating a language processing discrepancy (English: 75.4% vs Korean: 67.8%; difference 7.5%; 95% CI 3.1%-11.9%; P=.001). Conclusions: This study underscores the potential of AI tools, such as ChatGPT, in medical education and practice but emphasizes the need for cautious application and further refinement, especially in non-English medical contexts. The findings suggest that although AI advancements are promising, they require careful evaluation and development to ensure acceptable performance across diverse linguistic and professional settings.
- 16 September 2024
- Published by JMIR Publications Inc. in JMIR Medical Education
- Vol. 10, e56859
Open AccessPerformance of ChatGPT in the In-Training Examination for Anesthesiology and Pain Medicine Residents in South Korea: Observational Study
Background: ChatGPT has been tested in health care, including the US Medical Licensing Examination and specialty exams, showing near-passing results. Its performance in the field of anesthesiology has been assessed using English board examination questions; however, its effectiveness in Korea remains unexplored. Objective: This study investigated the problem-solving performance of ChatGPT in the fields of anesthesiology and pain medicine in the Korean language context, highlighted advancements in artificial intelligence (AI), and explored its potential applications in medical education. Methods: We investigated the performance (number of correct answers/number of questions) of GPT-4, GPT-3.5, and CLOVA X in the fields of anesthesiology and pain medicine, using in-training examinations that have been administered to Korean anesthesiology residents over the past 5 years, with an annual composition of 100 questions. Questions containing images, diagrams, or photographs were excluded from the analysis. Furthermore, to assess the performance differences of the GPT across different languages, we conducted a comparative analysis of the GPT-4’s problem-solving proficiency using both the original Korean texts and their English translations. Results: A total of 398 questions were analyzed. GPT-4 (67.8%) demonstrated a significantly better overall performance than GPT-3.5 (37.2%) and CLOVA-X (36.7%). However, GPT-3.5 and CLOVA X did not show significant differences in their overall performance. Additionally, the GPT-4 showed superior performance on questions translated into English, indicating a language processing discrepancy (English: 75.4% vs Korean: 67.8%; difference 7.5%; 95% CI 3.1%-11.9%; P=.001). Conclusions: This study underscores the potential of AI tools, such as ChatGPT, in medical education and practice but emphasizes the need for cautious application and further refinement, especially in non-English medical contexts. The findings suggest that although AI advancements are promising, they require careful evaluation and development to ensure acceptable performance across diverse linguistic and professional settings.
- Top Cited PapersOpen Access
- 1 February 2024
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 77 (1) , 31-45
Surgical pleth index monitoring in perioperative pain management: usefulness and limitations
Surgical pleth index (SPI) monitoring is a representative, objective nociception-monitoring device that measures nociception using photoplethysmographic signals. It is easy to apply to patients and the numerical calculation formula is intuitively easy to understand; therefore, its clinical interpretation is simple. Several studies have demonstrated its efficacy and utility. Compared with hemodynamic parameters, the SPI can detect the degree of nociception during surgery under general anesthesia with greater accuracy, and therefore can provide better guidance for the administration of various opioids, including remifentanil, fentanyl, and sufentanil. Indeed, SPI-guided analgesia is associated with lower intraoperative opioid consumption, faster patient recovery, and comparable or lower levels of postoperative pain and rates of adverse events compared with conventional analgesia. In addition, SPI monitoring allows for the degree of postoperative pain and analgesic requirements to be predicted through the SPI values immediately before patient arousal. However, because patient age, effective circulating volume, position, concomitant medication and anesthetic regimen and level of consciousness may be confounding factors in SPI monitoring, clinicians must be careful when interpreting SPI values. In addition, as SPI values can differ depending on anesthetic and analgesic regimens and the underlying disease, an awareness of the effects of these variables with an understanding of the advantages and disadvantages of SPI monitoring compared to other nociception monitoring devices is essential. Therefore, this review aimed to help clinicians perform optimal SPI-guided analgesia and to assist with the establishment of future research designs through clarifying current usefulness and limitations of SPI monitoring in perioperative pain management.
- 1 February 2024
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 77 (1) , 31-45
Top Cited PapersOpen AccessSurgical pleth index monitoring in perioperative pain management: usefulness and limitations
Surgical pleth index (SPI) monitoring is a representative, objective nociception-monitoring device that measures nociception using photoplethysmographic signals. It is easy to apply to patients and the numerical calculation formula is intuitively easy to understand; therefore, its clinical interpretation is simple. Several studies have demonstrated its efficacy and utility. Compared with hemodynamic parameters, the SPI can detect the degree of nociception during surgery under general anesthesia with greater accuracy, and therefore can provide better guidance for the administration of various opioids, including remifentanil, fentanyl, and sufentanil. Indeed, SPI-guided analgesia is associated with lower intraoperative opioid consumption, faster patient recovery, and comparable or lower levels of postoperative pain and rates of adverse events compared with conventional analgesia. In addition, SPI monitoring allows for the degree of postoperative pain and analgesic requirements to be predicted through the SPI values immediately before patient arousal. However, because patient age, effective circulating volume, position, concomitant medication and anesthetic regimen and level of consciousness may be confounding factors in SPI monitoring, clinicians must be careful when interpreting SPI values. In addition, as SPI values can differ depending on anesthetic and analgesic regimens and the underlying disease, an awareness of the effects of these variables with an understanding of the advantages and disadvantages of SPI monitoring compared to other nociception monitoring devices is essential. Therefore, this review aimed to help clinicians perform optimal SPI-guided analgesia and to assist with the establishment of future research designs through clarifying current usefulness and limitations of SPI monitoring in perioperative pain management.